Profund Advisors LLC Boosts Stock Position in Halozyme Therapeutics, Inc. $HALO

Profund Advisors LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 40.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,440 shares of the biopharmaceutical company’s stock after acquiring an additional 11,021 shares during the period. Profund Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,000,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alliancebernstein L.P. boosted its holdings in Halozyme Therapeutics by 4.8% in the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock worth $205,156,000 after buying an additional 146,677 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Halozyme Therapeutics by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock worth $129,478,000 after purchasing an additional 95,600 shares during the period. TD Asset Management Inc grew its stake in shares of Halozyme Therapeutics by 5.8% in the first quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company’s stock valued at $92,642,000 after buying an additional 79,708 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its position in Halozyme Therapeutics by 27.3% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock valued at $72,107,000 after acquiring an additional 242,167 shares in the last quarter. Finally, Los Angeles Capital Management LLC increased its stake in Halozyme Therapeutics by 951.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock worth $50,650,000 after buying an additional 881,094 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.01 on Tuesday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The business’s 50-day simple moving average is $70.56 and its 200-day simple moving average is $62.95. The firm has a market capitalization of $8.00 billion, a P/E ratio of 15.56, a P/E/G ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. During the same quarter last year, the firm earned $1.27 earnings per share. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $55,285,726.65. This represents a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 88,227 shares of company stock valued at $6,509,395. 2.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Benchmark raised their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday. Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Finally, Morgan Stanley cut their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.